Saudi Arabia – Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm
22/09/2020 No Comments
Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.
Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.
These results are evidences to support the early use of HCQ in post exposure prophylaxis.
To have covered up the knowledge for four decades that viruses could potentially be treated by antimicrobials required extensive effort
In this trial, no deaths occurred related to hydroxychloroquine, and serious side effects were rare.
An Urgent Call to Depoliticize Medicine in the COVID-19 Pandemic
HCQ or CQ should be used efficiently alone or in combination with AZ to optimize the management of asymptomatic and mild cases of COVID-19.
‘’Treatment with an oral combination of hydroxychloroquine, azithromycin and zinc may REPRESENT THE BEST CURRENT THERAPEUTIC OPTION in relation to its antiviral and immunomodulatory effects’’.
We believe this study is fatally flawed: “Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis”.
This is an Indian study about the use of hydroxychloroquine for infection prevention against COVID-19. This study has not released any official data yet.
Asian countries overall have fared better in controlling Covid-19, with lower mortality which is due to demographics and use of HCQ.
Dr. John Campbell Belgium, not Dutch. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants (International Journal
TRANSLATED Source: le journal du medecin by Frédéric Soumois A retrospective study published in the International Journal of Antimicrobial Agents examined the effect of hydroxychloroquine given to
A Belgian study has just been published, on 8,000 patients, and concludes that hydroxychloroquine reduces mortality by 30%
The study concluded that hydroxychloroquine can be effective when given early after a COVID-19 diagnosis, and there was no negative side effects.
HCQ and AZI are safe in haemodialysis patients at these doses, and HCQ concentrations were not correlated with side effects.
In this study, SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization.
Our study, including a large sample of patients hospitalized with COVID-19 in Italy, shows HCQ use had a 30% reduction of overall in-hospital mortality.
HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Our data doesn’t discourage use of HCQ in inpatients with COVID-19.
This Multicenter Study shows that the risk of death is 30% lower for coronavirus patients treated with hydroxychloroquine.
Source: Freshers Live Author: IANS A study in Belgium that went through the hospital data of 8,075 patients has found that low doses of hydroxychloroquine
Corticosteroid treatment didn’t correlate with death in our model whereas both hydroxychloroquine and azithromycin correlated with a lower mortality rate.
Indeed, following bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of ICU admission (P=0.008).
This data states that early care of COVID-19 patients at retirement homes can be effective in saving lives when treated with hydroxychloroquine.
What If a person advocated that parachutes don’t work, we should ban usage and pilots who give a parachute to skydivers should lose their pilot’s license
Hydroxychloroquine for COVID patients in moderate cases within the recommendation and use criteria, is safe, highly tolerable, and with little side effects.
The 5-day course of HCQ -AZM combination did not lead to significant QT prolongation and other conduction delays compared to baseline ECG in non-ICU COVID19(+) patients.
HCQ treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries.
Source: Springer Link Dear Editor, The coronavirus disease 2019 (COVID-19) pandemic caused by widespread infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Chen
The evidence shown in this work let us think that Zn(II) indeed may play a role in the viral cell cycle, and zinc ionophores boost zinc’s effects.
Source: Newsmax An Italian study found that hospitalized coronavirus patients who took anti-malaria drug hydroxychloroquine combined with azithromycin were 66% less likely to die. Science Direct reports that
Indeed, our study suggests that AZI±HCQ might have impacted COVID-19 outcome in a population of patients, optimal timing of treatment interventions to study
The metabolic inhibitors determine which pathways actively inhibits mitochondrial ATP production with hydroxychloroquine
Under ‘Time to resolution of symptoms’ in this article’s interactive diagram, it states that out of the studies referenced, “Hydroxychloroquine might be the most effective in
Scientists globally are protesting the studies that are biased or cover up the effectiveness of hydroxychloroquine by rendering the results statistically insignificant.
The report was based on observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically.
Source: Fox News – Ingraham By Joshua Nelson | Fox News Several studies found that early administration of hydroxychloroquine makes hospitalized patients substantially less likely to die Dr.
HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
Source: c19 Study A live and ongoing index of study data from around the world documenting the use of hydroxychloroquine in treatment at various stages
In this study of over 6000 hospitalized patients with COVID-19 in the New York City, hydroxychloroquine use was associated with decreased mortality.
Hydroxychloroquine use was associated with decreased mortality.